{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03104374_SELECT_PsA2\\NCT03104374_SELECT_PsA2_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug. The FAS will be used for all efficacy and baseline analyses.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set (FAS) includes all randomized subjects who received at least one dose of study drug. The FAS will be used for all efficacy and baseline analyses.",
        "criteria": "Randomized AND received >=1 dose of study drug"
      },
      {
        "id": "pop_2",
        "name": "Per Protocol Analysis Set",
        "text": "The Per Protocol Analysis Set represents a subset of the FAS and consists of all FAS subjects who did not have any major protocol deviations that are determined to have a potential impact on the primary efficacy endpoint up to Week 12 in Period 1 of the study.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PPS",
        "populationDescription": "The Per Protocol Analysis Set represents a subset of the FAS and consists of all FAS subjects who did not have any major protocol deviations that are determined to have a potential impact on the primary efficacy endpoint up to Week 12 in Period 1 of the study.",
        "criteria": "FAS subject AND no major protocol deviations affecting primary efficacy endpoint through Week 12"
      },
      {
        "id": "pop_3",
        "name": "Safety Analysis Set",
        "text": "The Safety Analysis Set consists of all subjects who received at least one dose of study drug. For the Safety Analysis Set, subjects will be analyzed 'as treated,' regardless of the treatment randomized.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The Safety Analysis Set consists of all subjects who received at least one dose of study drug. For the Safety Analysis Set, subjects will be analyzed 'as treated,' regardless of the treatment randomized.",
        "criteria": "Received >=1 dose of study drug"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Sex",
        "code": "SEX",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Sex",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Biological sex of the participant"
      },
      {
        "id": "char_2",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age in years at baseline"
      },
      {
        "id": "char_3",
        "name": "Weight",
        "code": "WEIGHT",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Weight",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Weight in kg at baseline"
      },
      {
        "id": "char_4",
        "name": "Duration of PsA symptoms",
        "code": "DURATION_OF_PSA_SYMP",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Duration of PsA symptoms",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Duration of Psoriatic Arthritis symptoms in years"
      },
      {
        "id": "char_5",
        "name": "Tender joint count (TJC68)",
        "code": "TENDER_JOINT_COUNT_(",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Tender joint count (TJC68)",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Number of tender joints out of 68 assessed joints"
      },
      {
        "id": "char_6",
        "name": "Swollen joint count (SJC66)",
        "code": "SWOLLEN_JOINT_COUNT_",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Swollen joint count (SJC66)",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Number of swollen joints out of 66 assessed joints"
      },
      {
        "id": "char_7",
        "name": "hsCRP",
        "code": "HSCRP",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "hsCRP",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "High sensitivity C-reactive protein"
      }
    ],
    "summary": {
      "populationCount": 3,
      "characteristicCount": 7
    }
  }
}